Last reviewed · How we verify
Tramadol HCl Twice a day
Tramadol HCl is a centrally acting opioid analgesic that works by binding to opioid receptors in the brain and spinal cord, reducing pain perception.
Tramadol HCl is a centrally acting opioid analgesic that works by binding to opioid receptors in the brain and spinal cord, reducing pain perception. Used for Moderate to moderately severe pain, Severe pain.
At a glance
| Generic name | Tramadol HCl Twice a day |
|---|---|
| Sponsor | Labopharm Inc. |
| Drug class | Opioid analgesic |
| Target | mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | Phase 3 |
Mechanism of action
Tramadol HCl is a weak mu-opioid receptor agonist and a norepinephrine reuptake inhibitor. It also inhibits the reuptake of serotonin, which contributes to its analgesic effects. By binding to opioid receptors, tramadol HCl reduces the transmission of pain signals to the brain, providing pain relief.
Approved indications
- Moderate to moderately severe pain
- Severe pain
Common side effects
- Nausea
- Dizziness
- Headache
- Somnolence
- Constipation
Key clinical trials
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain (NA)
- Efficacy and Safety of Canadá Association in the Treatment of Chronic Pain (PHASE2)
- PROUD Study - Preventing Opioid Use Disorders (PHASE4)
- A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain (PHASE3)
- Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain (PHASE2, PHASE3)
- Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients (PHASE4)
- Postoperative Effects of TAP Block Versus QLB Type 2 Block (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tramadol HCl Twice a day CI brief — competitive landscape report
- Tramadol HCl Twice a day updates RSS · CI watch RSS
- Labopharm Inc. portfolio CI